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preparation, Vero cells were expanded using two pre-culture steps 
and cell culture followed by virus culture. "e PV was puri#ed using 
normal $ow #ltration for clari#cation, tangential $ow #ltration for 
concentration and followed by two chromatography steps involving 
size exclusion and ion exchange chromatography. Puri#ed virus was 
inactivated using formaldehyde. Subsequently the IPVs were mixed 
to obtain trivalent bulk prior to formulation and #lling [1]. Due to the 
need to cultivate large amounts of the live poliovirus which involved 
complex manufacturing and puri#cation processes, exposure of 
workers to the live virus must be safely guarded. At the Cutter 
Laboratories, insu%cient inactivation of the IPV led to paralysis in 
almost 200 vacinees and their contacts [2]. "is incident resulted in 
the temporary halt of the use of IPV and encouraged research groups 
worldwide to produce a live attenuated polio vaccine. Although IPV 
has an excellent track record on e%cacy, it had poor induction of 
intestinal immunity, required cold-chain, booster injections and had 
expensive and potentially dangerous manufacturing processes with 
the wild type virulent virus. As such, large-scale clinical trials were 
Introduction
Polio virus vaccines
Inactivated polio vaccine: Poliovirus (PV) is the etiological 
agent of poliomyelitis and belongs to Enterovirus species C within 
the Picornaviridae family. Poliomyelitis was a public health scare in 
the 1950s, even in countries with the best health systems and hygiene 
practices in place. "is thereby led to the raising of funds to support 
research in the development of a polio vaccine. "e Inactivated 
Poliovirus Vaccine (IPV) was the #rst poliovirus vaccine to be 
licensed in 1955. IPV was developed by Salk et al. (1954) and was 
prepared by formalin-inactivation of three wild-type virulent strains 
which are the Mahoney (type 1), MEF-1 (type 2) and Saukett (type 
3). "e United States started using the IPV and it showed such high 
e%cacy that other countries around the world started to follow suit. 
Although IPV is considered safe, there is a risk of exposure to the 
wild type strain during the manufacturing process.  Figure 1.1 shows 
the manufacturing process for the IPV. During monovalent bulk 
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evaluated using several live attenuated PV strains [3].
Oral polio virus vaccine: "e Oral Poliovirus Vaccine (OPV) is 
an attenuated vaccine which has reduced worldwide poliomyelitis 
caused by PV infection. "e IPV was the only poliovirus vaccine 
available until licensure of the Oral Poliovirus Vaccine (OPV) in 
1963. "ere was a need for an OPV then as it is a live attenuated 
vaccine which has long-lasting immune response but requires several 
boosters, is safe and e&ective [4]. Elimination of poliomyelitis in the 
developing world was achieved mainly through mass vaccination with 
the OPV despite its ability to revert to the wild type in an estimated 1 
out of 250, 000 to 1 out of 800, 000 [5,6].
"e OPV was produced by micro-carrier technology and passage 
of the virus in primary monkey kidney cells at sub-physiological 
temperatures that generated spontaneous mutations in the viral 
genome [7]. "e mutated strains with low virulence were selected 
and used as vaccines. "e process was later scaled up by using 750-
L bioreactors and replacing tertiary monkey kidney cells with Vero 
cells [1]. "is has led to successful production of Oral Polio Vaccines 
(OPV) which have reduced worldwide poliomyelitis by the mid-
1980s. 
As such, the World Health Assembly declared in 1988 that polio 
should be eradicated by the year 2000, aligned with the success of 
the smallpox eradication program. However, the eradication deadline 
was repeatedly postponed and has not been met till today due to low 
vaccination coverage. "is is due to the fact that there are several 
countries where polio persistently remained endemic such as in 
Pakistan and Afghanistan. "erefore, there is a need to have a greater 
understanding of the molecular determinants of neurovirulence in PV 
to develop new and better vaccines based on genetic manipulations 
to render the virus non-pathogenic, yet containing similar antigenic 
structures to the wild type polio virus. 
Molecular determinants of neurovirulence: "e polio virus is 
an enterovirus from the family Picornaviridae. "e PV has a 5’ Non-
Translated (NTR) cloverleaf structure and a 3’-poly (A) tail. Domain 
I is important for virus replication and domains II-VI encompass the 
Internal Ribosome Entry Site (IRES) that directs translation of mRNA 
by internal ribosome binding (Figure 1.2). If there are mutations in 
the 5’-NTR, this decreases multiplication e%ciency, alters cell tropism 
and attenuates virulence [8]. 
"ere are three attenuated strains being used as OPV: Sabin 
1 was derived from the Mahoney strain, Sabin 2 was derived from 
the P172 strain and Sabin 3 was derived from the Leon strain. 
Identi#cation of the genetic determinants of attenuation of the Sabin 
OPV strains has been comprehensively reviewed [8]. "e complete 
sequences of the three poliovirus genomes and the development 
of infectious poliovirus Complementary Deoxyribonucleic Acid 
(cDNA) clones have led to the systematic investigations of the 
critical mutations responsible for the attenuated phenotypes of the 
Sabin OPV strains. From the analysis of Nucleotide (NT) sequences 
present in the three poliovirus Sabin strains, nucleotide substitutions 
which were critical in attenuating mutations in the virulent strains 
isolated from cerebrospinal $uid were identi#ed. "ere are 57 
nucleotide substitutions distinguishing the Sabin 1 strain from its 
parent strain [9]. Among these nucleotide substitutions, the A480G 
in the IRES is the most important determinant of the attenuated 
phenotype of Sabin 1. "eir studies strongly suggested that nt. 480 
in$uences the formation of a highly ordered structure in the 5’-NTR 
that is responsible for neurovirulence [10]. Four other nucleotide 
substitutions contributing to the attenuated phenotype were mapped 
to the capsid region. "ere was one in VP4, one in VP3 and two in 
VP1. In addition, there was also one substitution that contributed 
to the temperature-sensitive phenotype mapped to the 3DPol region 
[11,12]. 
However, there were only 2 nt. substitutions found in the Sabin 
2 strain that appeared at position 481 within the IRES region and 
position 2909 within VP1 (Figure 1.3). For Sabin 3, a total of 10 nt. 
Figure 1.1: Process overview for preparation of trivalent IPV. Monovalent 
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substitutions were found to di&er from its parent strain, but only 3 
substitutions appeared to be the main determinants for the attenuated 
phenotype (C274U in IRES, C2034U in VP3, and U2493C in VP1) 
[13]. Sabin 3 strain was also found to be the most genetically unstable 
of the three Sabin strains. As a result of the analysis of the molecular 
determinants of attenuation, in vitro construction of piconaviruses 
with reduced-virulence could be performed via the introduction of 
mutations in the 5’-NTR to reduce the e%ciency of viral replication. 
Recent advances in developing new polio vaccines: In 2000, 
the Advisory Committee on Immunization Practices (ACIP) has 
recommended only the use of Inactivated Poliovirus Vaccine (IPV) 
for childhood polio vaccination in the United States and subsequently, 
for other countries. All children would receive four doses of IPV at 
ages 2, 4, 6-18 months and 4-6 years. "e ACIP wanted to decrease the 
risk of Vaccine-Derived Poliovirus (VDPV) and Vaccine Associated 
Poliomyelitis (VAPP) (ranging from 1 in 700, 000 to 1 in 3.4 million 
#rst doses), yet still maintain the bene#ts of OPV [14,15]. "e risk-
bene#t equation altered a*er eradication of wild type poliomyelitis in 
industrialised countries and the only source of poliomyelitis seemed 
to be derived only from the OPV [16].
Due to this gradual shi* from OPV back to IPV, one of the 
most anticipated next generation vaccines is an IPV based on the 
attenuated Sabin poliovirus strains, producing a Sabin IPV (sIPV), 
also known as the enhanced IPV [17]. "e sIPV is manufactured 
from attenuated Sabin virus strains instead of wild-type PVs. In 
addition, it has already been used in Japan for the past 3 years in their 
routine immunization program and currently licensed in China to be 
introduced in routine immunization in several provinces. "ey would 
be expected to be in high demand to enhance worldwide production 
of the sIPV. "e cost of sIPV production has increased [18] since the 
World Health Organisation (WHO) launched the Global Action Plan 
for Wild Poliovirus Laboratory Containment III (GAPIII) to make 
biosafety requirements more stringent. As a result of the GAPIII, 
manufacturing costs for sIPV have increased signi#cantly, leading 
to challenges in implementation especially in developing countries 
where they are most needed.
Although there is data to support broad protection of the sIPV 
at varying e%cacies, more studies have to be conducted on issues 
concerning the quality control, evaluation of the sIPV and strategies 
to make the sIPV a&ordable for low-income countries where they 
are needed the most [19]. Hence, WHO had convened a technical 
working group on May 2013 participated by world-wide experts from 
academia and the industry who are involved in the development, 
manufacture, authorization and testing of sIPV. As a result, WHO 
has incorporated such concerns into its publication of technical 
guidelines for the quality, safety and e%cacy of the sIPV vaccine to 
assist in the production and control of sIPV [20].
Hence, alternative vaccine strains that require less stringent bio-
containment and manufacturing processes that can be carried out 
in developing countries are much needed. "is approach potentially 
lowers production costs and is encouraged by the WHO [21]. By 
the beginning of the 21st century, most developed countries have 
switched exclusively to IPV. As such, there have been much studies 
performed to produce a third generation IPV. "is new generation of 
IPV di&ers from the sIPV as it is produced from poliovirus strains that 
have an antigenic structure identical to the currently used wild-type 
strains but were rendered non-pathogenic by genetic manipulations. 
"is was carried out through several methods like modi#cation of 
the 5?-NTR of the poliovirus genome, mutation of the poliovirus 
3D polymerase gene, utilising codon-pair bias de-optimization and 
microRNA sequence insertion [16].
One of the most important virulence determinants in the 
poliovirus is in the Internal Ribosome Entry Site (IRES) within the 5’-
NTR of the PV RNA. Hence, manipulation of the IRES with multiple 
nucleotide substitutions, insertions or deletions could be used to 
create a more stable attenuated PV strain for IPV manufacture 
[22,23]. Inclusion of weaker base pairing also reduces the stability 
of the IRES region and thereby, decreases the rate of reversion 
[24]. Another approach would be to introduce mutations in the 3D 
Polymerase gene sequence of the PV [25] that can increase replication 
#delity and reduce pathogenicity. "ese mutations could reduce viral 
virulence, yet retain the antigenic properties of the wild type PV. 
An increasingly popular approach would be to carry out codon-
pair bias deoptimization. "is is based on the fact that there are 
preferred combinations of neighbouring codons. Hence, by swapping 
di&erent but synonymous codons within the same sequence will result 
in changed pairs of codons but the original amino acid sequence 
Figure 1.4: The difference between a VLP and virus particle???????????????
???????????????????? ?????????????????? ???????????????????????????????????????
??????????????????????????????????????????????? Figure 1.5: Production of genetically-stable OPV strains?? ???? ???? ??????????????????????????????????????????????????????????????????????????????
???????????????????????????????????????????????????????????????????????????
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was retained. "is was observed by Coleman et al. who carried out 
the deoptimization approach that led to decreased viral #tness and 
the overall attenuation in PV neurovirulence [26]. Who carried out 
the deoptimization approach that led to decreased viral #tness and 
an overall attenuation in PV neuro-virulence? "ey discovered that 
deoptimization decreased signi#cantly the quantity of infectious 
PV although the number of virus particles remained the same. "is 
implies that although the infectious viral titre decreased, the amount 
of antigen required for making the IPV remained su%cient.
Recent studies have demonstrated another emerging approach 
that could represent an attractive addition to the current research 
on IPV. Eukaryotic cells produce microRNAs (miRNA) that are 20-
24 nucleotides long, non-coding RNAs that can increase or prevent 
translation of messenger RNA (mRNA) by binding to it and causing 
cleavage or translational block, dependent on sequence homology 
with target mRNA [27]. By manufacturing short RNA pieces that are 
complementary to mRNA prevalent in tissues that are viral targets, 
this could reduce pathogenicity. Barnes et al. (2008) engineered 
poliovirus to carry neuronal-speci#c miR-124 RNA which prevented 
viral replication in the central nervous system and thus led to 
signi#cant attenuation of neurovirulence in infected mice. "ese 
viruses could also be grown for IPV production in cultured cells that 
do not express this particular miRNA [28].
Such modi#cations have been carried out by various research 
groups and reviewed by [19]. An investigation by [1]. An investigation 
by "omassen et al. produced an IPV at industrial scale that met 
quality criteria, were immunogenic in rats, showed no toxicity in 
rabbits and could be released for testing in clinical phase I/IIa [1]. In 
addition, Japan has developed two IPVs that have already received 
market authorization [29]. "e Chinese Academy of Medical 
Sciences (CAMS) in Kuming, China had completed clinical Phase 
III studies for their IPV. "e following PV master seeds were used 
by CAMS: For type 1 PV, Sabin SO+1; for Type 2, Sabin SO+1; for 
Type 3, P#zer RS01."e micro-carrier culture method was utilised to 
cultivate Vero cells and PV in bioreactors. For their Clinical Phase II, 
a randomized, positive-controlled trial was conducted in 500 infants 
that were randomly assigned to 5 groups (A, B, C, D, and E). A*er 3 
doses, the seroconversion rates for types 1, 2 and 3 poliovirus were 
similar to those of the OPV and IPV control groups. "ey reported 
seroconversion rates of 100%, 97.8%, 96.6%, 100%, and 90.1%, 
respectively, in groups A, B, C, D, and E for the type 1 PV [30].
Interestingly, the National Institute for Biological Standards and 
Control (NIBSC) are developing the production of thermostable PV 
Virus-Like Particles (VLP) using recombinant mammalian, yeast, 
bacterial, baculovirus and plant expression systems in collaboration 
with several UK laboratories. VLPs are devoid of viral RNA but 
are produced naturally during PV infections. "e external surface 
of a VLP is indistinguishable from that of a PV particle but several 
internal amino acid chains are disordered (Figure 1.4). NIBSC have 
identi#ed several amino acid substitutions that stabilise VLPs without 
altering antigenicity and these VLPs appear are as thermostable as the 
current IPV.
In addition, NIBSC is also trying out an approach to produce 
genetically-stable OPV strains. "e 5’-NTR of the PV genome which 
contains domain V, forms part of a larger structure that controls 
initiation of translation. "e level of attenuation is determined by 
its thermodynamic stability. "ey have modi#ed domain V to make 
it genetically stable by removing all the U-G base-pairs (Figure 1.5). 
Any single mutation in base-paired stems would weaken the domain 
V and generate a more attenuated virus. In order to increase the 
genetic stability of this attenuated strain, NIBSC researchers have also 
moved an essential Cis-acting replication element (cre) from the P2 
region to a position near the 5’ end to reduce the risk of loss of this 
part of the genome through recombination (Figure 1.5). In this way, 
two recombination events would be required to replace domain V 
which is highly unlikely. As the 3D Polymerase also plays an integral 
role in attenuation of viruses, NIBSC scientists have collaborated with 
researchers at the University of California to introduce mutations 
that would increase the #delity of the 3D polymerase and decrease its 
ability to catalyse homologous recombination [31].
Conclusion
A*er eradication of wild type poliomyelitis in industrialised 
countries, the only source of polio seemed to be derived from cases of 
VAPP and VDPVs that inevitably could lead to potential outbreaks. 
Due to a gradual shi* of polio vaccination from OPV back to IPV, 
one of the most anticipated next generation vaccines is an IPV based 
on the attenuated Sabin poliovirus strains, producing a Sabin IPV 
(sIPV). "e sIPV has good clinical trial data by research groups in 
USA, Japan and China to support the use of the vaccine. In addition, 
there have been several studies performed to produce a third 
generation IPV. "is new generation of IPV di&ers from the sIPV as 
it is produced from poliovirus strains that have an antigenic structure 
identical to the wild-type strains but were non-pathogenic by genetic 
manipulations like modi#cation of the 5? -NTR of the poliovirus 
genome, mutation of the poliovirus 3D polymerase gene, utilising 
codon-pair bias de-optimization and microRNA sequence insertion. 
However, technological advances in the development of the sIPV 
or 3rd generation IPV will not result in universal global protection 
against poliomyelitis unless they are supported by a sustainable 
public health infrastructure for vaccine distribution, coverage and 
use. "ere should also be mobilization of e&orts from both the public 
and private organizations in order to achieve success of the polio 
eradication initiative. 
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